Tango Therapeutics, Inc. — Earnings Quality Grade D
TNGX · Healthcare
Significant concerns
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue grew 48.3% but CFFO declined -5.6%
Expense Quality
No material inventory
CapEx growth 39.0% vs revenue 48.3%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 1.37. Profits backed by cash
FCF is negative ($-0.1B)
Accruals ratio = 9.4%. Elevated
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.3x. Healthy
Other assets -5.0% vs revenue 48.3%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor TNGX continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25